European drug agency criticises Roche for failing to report adverse reactions and patient deaths
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e4344 (Published 26 June 2012) Cite this as: BMJ 2012;344:e4344- Jacqui Wise
- 1London
The Swiss company Roche has been criticised for failing to inform the European Medicines Agency of up to 80 000 possible adverse reactions from its drugs, including 15 161 deaths in the United States.
The reports had been collected through a US patient support programme sponsored by Roche but had not been included in the company’s global safety database as required by the European agency’s pharmacovigilance regulations.
The reports related to a range of drugs provided by Genentech, Roche’s US subsidiary. Genentech produces cancer treatments, such as bevacizumab (which it markets as Avastin) and trastuzumab (Herceptin), and ranibizumab (Lucentis) …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.